|
Secondary Private Group
|
|
28
|
23504
|
8 May 2024
|
|
Researching trials and treatments abroad
|
|
1
|
100
|
10 May 2024
|
|
Licensing new drug Tucatinib (TUKYSA), from HER2CLIMB trial
|
|
4
|
3316
|
8 May 2024
|
|
Advice please re. new diagnosis
|
|
17
|
648
|
8 May 2024
|
|
Covid booster 2024
|
|
12
|
405
|
5 May 2024
|
|
Exemestane (aromasin) and Everolimus (Afinitor)
|
|
19
|
1023
|
1 May 2024
|
|
Enhertu
|
|
21
|
15478
|
30 April 2024
|
|
Liver Mets and bloating
|
|
1
|
233
|
27 April 2024
|
|
BCN Response Time
|
|
6
|
388
|
27 April 2024
|
|
Oral thrush - Candida. What next?
|
|
9
|
1065
|
27 April 2024
|
|
Eribulin
|
|
3
|
979
|
12 April 2024
|
|
Atrophy
|
|
11
|
508
|
31 March 2024
|
|
Is Enhertu available in the UK, on the NHS
|
|
20
|
910
|
18 March 2024
|
|
Have you recieved elacestrant (orserdu)?
|
|
0
|
145
|
18 March 2024
|
|
Xgeva (denosumab) and low White blood count
|
|
1
|
186
|
16 March 2024
|
|
Change of treatment - PICC or central line
|
|
12
|
283
|
16 March 2024
|
|
Capecitabine older people
|
|
7
|
279
|
16 March 2024
|
|
CA15-3 marker
|
|
7
|
571
|
16 March 2024
|
|
Weight gain in short space of time ?
|
|
5
|
632
|
13 March 2024
|
|
Tamoxifen Brand Change
|
|
3
|
175
|
10 March 2024
|
|
Post surgery anxiety
|
|
6
|
330
|
18 February 2024
|
|
Terrible balance problem
|
|
7
|
382
|
8 February 2024
|
|
Cancer Research Awareness
|
|
0
|
151
|
4 February 2024
|
|
Xeloda and bone recurrence
|
|
3
|
331
|
31 January 2024
|
|
Atezolizumab and Nab-paclitaxel (Abraxane) experience
|
|
5
|
945
|
30 January 2024
|
|
About to start Trodelvy, any information please
|
|
6
|
3356
|
28 January 2024
|
|
Xeloda delay
|
|
13
|
488
|
21 January 2024
|
|
The dreaded canula
|
|
12
|
507
|
11 January 2024
|
|
Sacituzumab govitecan (Trodelvy)
|
|
3
|
441
|
11 January 2024
|
|
HER2-low trastuzumab deruxtecan (Enhertu)
|
|
1
|
1235
|
1 January 2024
|